Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2 OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA

NCT05116046 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05116046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05116046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2 OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
December 24, 2021
Completion date
March 30, 2023
Enrollment
35 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

achondroplasia